Back to Search
Start Over
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
- Source :
- GlobeNewswire. September 15, 2023
- Publication Year :
- 2023
-
Abstract
- Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administration European Commission (EC) decision [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.765314997